DRAKO Non-interventional Study
DRAKO-An observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in patients with visual impairment due to diabetic macular oedema(DMO)
Duration of Study in the UK
3 years, 0 months, 2 days
The purpose of this observational study is to obtain information on how effective aflibercept (Eylea®) is in real life clinical settings and how it is actually being used in clinics. Aflibercept is already licensed (approved by the UK medicines regulatory authority).
The study will involve approximately 750 patients who are undergoing aflibercept treatment for Diabetic Macular Oedema (DMO) in approximately 30 study centres located throughout the United Kingdom.
North West - Liverpool East Research Ethics Committee
Date of REC Opinion
23 Mar 2016